» Articles » PMID: 34698088

Crosstalk Between Cancer Cells and Fibroblasts for the Production of Monocyte Chemoattractant Protein-1 in the Murine 4T1 Breast Cancer

Overview
Publisher MDPI
Specialty Molecular Biology
Date 2021 Oct 26
PMID 34698088
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2) is shown to promote the progression of breast cancer. We previously identified cancer cell-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) as a potential regulator of MCP-1 production in the murine 4T1 breast cancer, but it played a minimum role in overall MCP-1 production. Here, we evaluated the crosstalk between 4T1 cells and fibroblasts. When fibroblasts were co-cultured with 4T1 cells or stimulated with the culture supernatants of 4T1 cells (4T1-sup), MCP-1 production by fibroblasts markedly increased. 4T1 cells expressed mRNA for platelet-derived growth factor (PDGF)-a, b and c, and the PDGF receptor inhibitor crenolanib almost completely inhibited 4T1-sup-induced MCP-1 production by fibroblasts. However, PDGF receptor antagonists failed to reduce MCP-1 production in tumor-bearing mice. Histologically, 4T1 tumors contained a small number of αSMA-positive fibroblasts, and Mcp-1 mRNA was mainly associated with macrophages, especially those surrounding necrotic lesions on day 14, by in situ hybridization. Thus, although cancer cells have the capacity to crosstalk with fibroblasts via PDGFs, this crosstalk does not play a major role in MCP-1 production or cancer progression in this model. Unraveling complex crosstalk between cancer cells and stromal cells will help us identify new targets to help treat breast cancer patients.

Citing Articles

CCL2 signaling promotes skeletal muscle wasting in non-tumor and breast tumor models.

Alissa N, Fang W, Medrano M, Bergeron N, Kozai Y, Hu Q Dis Model Mech. 2024; 17(8).

PMID: 38973385 PMC: 11413935. DOI: 10.1242/dmm.050398.


The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis.

Yoshimura T, Li C, Wang Y, Matsukawa A Cell Mol Immunol. 2023; 20(7):714-738.

PMID: 37208442 PMC: 10310763. DOI: 10.1038/s41423-023-01013-0.


The Innate Immune Microenvironment in Metastatic Breast Cancer.

Tommasi C, Pellegrino B, Diana A, Palafox Sancez M, Orditura M, Scartozzi M J Clin Med. 2022; 11(20).

PMID: 36294305 PMC: 9604853. DOI: 10.3390/jcm11205986.

References
1.
Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M . Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer. 2009; 125(6):1276-84. DOI: 10.1002/ijc.24378. View

2.
Andersson U, Tracey K . HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29:139-62. PMC: 4536551. DOI: 10.1146/annurev-immunol-030409-101323. View

3.
Deguchi J, Abe J, Makuuchi M, Takuwa Y . Inhibitory effects of trapidil on PDGF signaling in balloon-injured rat carotid artery. Life Sci. 2000; 65(26):2791-9. DOI: 10.1016/s0024-3205(99)00547-0. View

4.
Usary J, Darr D, Pfefferle A, Perou C . Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes. Curr Protoc Pharmacol. 2016; 72:14.38.1-14.38.11. PMC: 4826719. DOI: 10.1002/0471141755.ph1438s72. View

5.
Dexter D, Kowalski H, Blazar B, Fligiel Z, Vogel R, Heppner G . Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 1978; 38(10):3174-81. View